- In order to be a cost-effective maintenance therapy for metastatic colorectal cancer (mCRC), the combination of capecitabine and bevacizumab would have to be 93% cheaper.
Why this matters
- The finding could help policymakers and inform payment negotiation.
- Markov model of outcomes data from the CAIRO phase 3 randomized clinical trial of 558 adults in the Netherlands.
- Funding: None disclosed.
- Patients lived an average of 2.88 months longer in the treatment group than in the observation group, at an additional cost of $105,217 (or $438,394 per life-year).
- Per-cycle drug costs were $6173.35 for capecitabine plus bevacizumab, including $62.05 for complication treatment during observation and $311.99 for complication treatment during maintenance therapy.
- Capecitabine + bevacizumab maintenance therapy led to a mean of 1.34 quality-adjusted life years (QALYs) vs 1.20 QALYs for observation, with a cost-effectiveness ratio of $725,601 per QALY.
- To reduce this cost to the median household income of $59,039, the combined cost for 3-week capecitabine plus bevacizumab cycle would have to be reduced from $6173 to $452.
- Calculations were made based on Medicare.
- Data from a clinical trial may not reflect real-world outcomes and costs.